CytoSite Bio
PrivateLast Round
Seed
Sep 24, 2020
Total Funding Raised
$7.87M
Company Overview
CytoSite Bio is a biotechnology company that develops Granzyme B-targeted radiopharmaceuticals and PET imaging agents to assess and improve immunotherapy efficacy in cancer and autoimmune disease patients.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Medical Imaging, Precision Medicine, Clinical Trials
Business Model
B2B
Customer Profile
Revenue Share, Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
CytoSite Bio Comparables
Compare CytoSite Bio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| CellSight Technologies | 87% | |
| Telix Pharmaceuticals | 79% | |
| GE HealthCare Technologies Inc. | 78% |
CytoSite Bio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Seed | Sep 24, 2020 | ||||
| Series A | Aug 9, 2018 |
Key People
Founding team and executive leadership
CytoSite Bio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| National Cancer Institute | Seed |
| NIH RADx | Grant |
| Acorn Campus Taiwan | Seed |
| First Avenue Ventures | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Mar 2, 2026
Monthly visitors grew 85% MoM.
- Sep 24, 2020
$3.05M round with Acorn Campus Taiwan and National Cancer Institute.
CytoSite Bio Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about CytoSite Bio's valuation, stock price, and market status.
Is CytoSite Bio a public or private company?
CytoSite Bio is a private company.
What is the current stock price of CytoSite Bio?
CytoSite Bio is a private company with no public stock price. No recent secondary market data is available.
How much is CytoSite Bio worth (valuation)?
Valuation information for CytoSite Bio is not publicly available.
Can I buy CytoSite Bio stock?
CytoSite Bio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was CytoSite Bio's last funding round?
CytoSite Bio's most recent funding round was Seed on September 24, 2020.
Who are the main investors in CytoSite Bio?
Key investors in CytoSite Bio include National Cancer Institute, NIH RADx, Acorn Campus Taiwan, First Avenue Ventures.
Will CytoSite Bio IPO soon?
No public IPO plans have been announced for CytoSite Bio.
How can I track CytoSite Bio secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor CytoSite Bio's secondary market activity and sign up for updates.